



MEMSCAP AND CARMAT COOPERATE FOR A NEW BIONIC HEART

An innovative MEMS Sensor for a fully implantable heart

Grenoble, France, Norway and Vélizy, France, January 5, 2010 – MEMSCAP (NYSE Euronext: MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical systems) technology and CARMAT, a Company specialized in the elaboration of biomaterials and advanced technologies applied to the field of artificial heart, today announce a partnership in the frame of development and industrialization of the first fully implantable artificial heart.

For MEMSCAP, this partnership confirms its major presence in the biomedical sector, through revolutionary products enhancing human lives. For CARMAT, this partnership, which benefits from MEMSCAP' experience and technologies, allows to realize spectacular progress in the development and industrialization of implantable artificial heart, thus contributing to save thousands of human lives.

The CARMAT patented artificial heart prototype respects the biocompatibility criteria enabling its implantation in the human body. Its features are similar to a biological heart, both on the physiological and the anatomy levels.

The system, composed from an implantable part, a portable part as well as external devices supplying power and assuring its control and monitoring, integrates MEMSCAP sensors to automatically regulate cardiac output and frequency in function of the patient physiological needs, such as physical effort.

“CARMAT has chosen to dedicate its activity to a major scientific challenge and to open new medical approaches. We are proud to help them realize those challenges and to offer an advanced system aiming to save multiple human lives », said Jan Hallenstvedt, General Manager of MEMSCAP' Standard Products Business Unit.

“MEMSCAP has been selected as we needed a partner having a strong experience in Microsystems capable of supplying us high quality products with extreme precision and very low time drift, showing strong robustness for many years », explained Marc Grimmé, Technical Director of CARMAT.

About MEMSCAP

MEMSCAP is the leading provider of innovative micro-electro-mechanical systems (MEMS)-based solutions. MEMSCAP standard and custom products and solutions include components, component designs (IP), manufacturing and related services. MEMSCAP customers include Fortune 500 businesses, major research institutes and universities. The company's shares are traded on the Eurolist of Euronext Paris S.A (ISIN: FR0010298620-MEMS), where MEMSCAP belongs to the Next Economy segment. More information on the company's products and services can be obtained at www.memscap.com

About CARMAT

Paris-based CARMAT was incorporated in June 2008 and financed by TRUFFLE CAPITAL (www.truffle.com), EADS (www.eads.com) and the Fondation Alain Carpentier, with additional funding from the French state innovation agency OSEO (<http://www.oseo.fr/>). The company has been spun out of a collaboration between the renowned surgeon Professor Carpentier and EADS on implementation of biomaterials and cutting-edge technologies in the construction of an artificial heart. CARMAT intends to market a fully implantable artificial heart that will be able to provide renewed hope and quality of life to the hundreds of thousands of patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible. For more information, visit the company's web site at www.carmatsas.com.

Contact:

Nicolas Bertsch
Director, R&D
MEMSCAP
Tel: +33 4 76 92 85 00

Marc Grimmé
Technical Director
CARMAT
Tel: +33 1 39 45 64 50